STEMLINE THERAPEUTICS INC's ticker is STML and the CUSIP is 85858C107. A total of 81 filers reported holding STEMLINE THERAPEUTICS INC in Q4 2017. The put-call ratio across all filers is 0.70 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $43,000 | -61.3% | 8,927 | -14.8% | 0.00% | – |
| Q4 2019 | $111,000 | +22.0% | 10,472 | +20.2% | 0.00% | – |
| Q3 2019 | $91,000 | -25.4% | 8,714 | +9.2% | 0.00% | – |
| Q2 2019 | $122,000 | +28.4% | 7,982 | +7.3% | 0.00% | – |
| Q1 2019 | $95,000 | +90.0% | 7,442 | +41.8% | 0.00% | – |
| Q4 2018 | $50,000 | -27.5% | 5,249 | +27.1% | 0.00% | – |
| Q3 2018 | $69,000 | +4.5% | 4,129 | 0.0% | 0.00% | – |
| Q2 2018 | $66,000 | -8.3% | 4,129 | -12.1% | 0.00% | – |
| Q1 2018 | $72,000 | -20.0% | 4,695 | -20.4% | 0.00% | – |
| Q4 2017 | $90,000 | +104.5% | 5,895 | +49.2% | 0.00% | – |
| Q3 2017 | $44,000 | +22.2% | 3,951 | 0.0% | 0.00% | – |
| Q2 2017 | $36,000 | +63.6% | 3,951 | +52.2% | 0.00% | – |
| Q1 2017 | $22,000 | -29.0% | 2,596 | -11.8% | 0.00% | – |
| Q4 2016 | $31,000 | – | 2,943 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lyon Street Capital, LLC | 1,471,518 | $23,618,000 | 8.40% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 492,930 | $7,862,000 | 3.02% |
| Consonance Capital Management LP | 2,747,198 | $44,093,000 | 2.84% |
| NEXTHERA CAPITAL LP | 559,517 | $8,980,000 | 1.39% |
| Eventide Asset Management | 1,086,400 | $17,437,000 | 0.72% |
| Virtus ETF Advisers LLC | 45,850 | $736,000 | 0.65% |
| KNOTT DAVID M | 90,000 | $1,445,000 | 0.54% |
| Polar Capital LLP | 1,912,605 | $30,697,000 | 0.18% |
| Artal Group S.A. | 400,000 | $6,420,000 | 0.14% |
| J. Goldman & Co LP | 100,000 | $1,605,000 | 0.08% |